Search Results

Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study.

• Authors : Chen G; Department of Pharmacy, Dongguan Hospital of Traditional Chinese Medicine, Dongguan, Guangdong, China.; Zhang L

Subjects: Phosphodiesterase 5 Inhibitors*/Phosphodiesterase 5 Inhibitors*/Phosphodiesterase 5 Inhibitors*/adverse effects ; Phosphodiesterase 5 Inhibitors*/Phosphodiesterase 5 Inhibitors*/Phosphodiesterase 5 Inhibitors*/administration & dosage ; Pharmacovigilance*

• Source: Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Jul; Vol. 23 (7), pp. 877-884. Date of Electronic Publication: 2024 May 16.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study.

• Authors : Burnett AL; Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.; Walker DR

Subjects: Adrenergic alpha-Antagonists/Adrenergic alpha-Antagonists/Adrenergic alpha-Antagonists/*therapeutic use ; Prostatic Hyperplasia/Prostatic Hyperplasia/Prostatic Hyperplasia/*complications ; Tadalafil/Tadalafil/Tadalafil/*therapeutic use

• Source: Neurourology and urodynamics [Neurourol Urodyn] 2020 Jun; Vol. 39 (5), pp. 1378-1386. Date of Electronic Publication: 2020 May 08.Publisher: Alan R. Liss Country of Publication: United States NLM ID: 8303326 Publication Model: Print-Electronic Cited

Record details

OPSYNVI(r) (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH).

• Source: Plus Company Updates. 2021.

Record details

Janssen Pharmaceutical Companies: OPSYNVI (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH).

• Source: Contify Life Science News. 2021.

Record details

U.S. FDA Approves OPSYNVI (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

• Source: PR Newswire. March 22, 2024

Record details

Tadalafil (Cialis) for erectile dysfunction.

• Authors : Noviasky, John A.; Masood, Asif; Lo, Vincent

• Source: American Family Physician. 2004, Vol. 70, Issue 2, pages. 359

Record details

Gilead Sciences Secures FDA Approval of New Treatment Combination of Letairis with Tadalafil.

• Source: Health & Beauty Close-Up. 2015.

Record details

Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH).

• Source: PR Newswire. March 6, 2023

Record details

Gilead Sciences Updates on Results of Ambrisentan and Tadalafil Study.

• Source: Professional Services Close-Up. 2014.

Record details

Gilead Sciences Reports Results of Ambrisentan and Tadalafil Study.

• Source: Health & Beauty Close-Up. 2014.

Record details